ICON Public Limited (NASDAQ:ICLR – Get Rating) hit a new 52-week low during trading on Thursday . The company traded as low as $197.28 and last traded at $198.16, with a volume of 1764 shares traded. The stock had previously closed at $205.59.
Several equities analysts recently issued reports on the stock. Wells Fargo & Company cut shares of ICON Public from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $280.00 to $250.00 in a research note on Monday, April 25th. Deutsche Bank Aktiengesellschaft raised ICON Public from a “hold” rating to a “buy” rating and upped their price target for the stock from $234.00 to $310.00 in a report on Monday, April 11th. Citigroup cut their price objective on ICON Public from $340.00 to $315.00 and set a “buy” rating for the company in a research report on Wednesday, February 23rd. Barclays decreased their target price on ICON Public from $285.00 to $255.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 23rd. Finally, Robert W. Baird reissued a “buy” rating and issued a $285.00 price target on shares of ICON Public in a report on Friday, May 13th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $284.40.
The company has a market cap of $16.15 billion, a PE ratio of 82.57, a PEG ratio of 1.13 and a beta of 0.97. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.13 and a current ratio of 1.13. The firm’s 50 day moving average is $225.55 and its 200-day moving average is $248.01.
ICON Public (NASDAQ:ICLR – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported $2.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.48 by $0.12. ICON Public had a return on equity of 11.33% and a net margin of 2.58%. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.88 billion. During the same period in the prior year, the business earned $2.06 earnings per share. On average, analysts predict that ICON Public Limited will post 10.67 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ICLR. TimesSquare Capital Management LLC increased its position in shares of ICON Public by 10.4% during the first quarter. TimesSquare Capital Management LLC now owns 249,900 shares of the medical research company’s stock valued at $60,781,000 after acquiring an additional 23,600 shares during the last quarter. Todd Asset Management LLC lifted its stake in ICON Public by 33.1% during the first quarter. Todd Asset Management LLC now owns 69,766 shares of the medical research company’s stock worth $16,950,000 after purchasing an additional 17,354 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of ICON Public by 19.8% during the third quarter. Captrust Financial Advisors now owns 29,027 shares of the medical research company’s stock worth $7,606,000 after buying an additional 4,805 shares during the period. Amundi Pioneer Asset Management Inc. grew its stake in shares of ICON Public by 2.1% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 24,400 shares of the medical research company’s stock valued at $3,332,000 after buying an additional 500 shares in the last quarter. Finally, FDx Advisors Inc. raised its holdings in shares of ICON Public by 1.7% in the 4th quarter. FDx Advisors Inc. now owns 19,191 shares of the medical research company’s stock valued at $5,943,000 after buying an additional 320 shares during the period. 89.41% of the stock is currently owned by institutional investors.
About ICON Public (NASDAQ:ICLR)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
Receive News & Ratings for ICON Public Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICON Public and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
